| Antibacterial Effect and Post-operative Pain Following Various Techniques of Intracanal Heating of NaOCL (NCT07420920) | Misr University for Science and Technology | 2026-02-10 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers (NCT07495514) | Addpharma Inc. | 2026-02-10 |
| A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) (NCT07371468) | GlaxoSmithKline | 2026-02-10 |
| Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19 (NCT07416539) | Rokote Laboratories Finland Oy | 2026-02-10 |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. (NCT07401862) | Eli Lilly and Company | 2026-02-10 |
| An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (NCT07461727) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-10 |
| A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (NCT07341373) | Portal Diabetes, Inc. | 2026-02-10 |
| Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD (NCT07418177) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-10 |
| First-Time-in-Human Study of GSK5471713 in Adults With mCRPC (NCT07332455) | GlaxoSmithKline | 2026-02-10 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (NCT07227415) | Pfizer | 2026-02-10 |
| A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV (NCT07392372) | BioNTech SE | 2026-02-09 |
| Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (NCT07269496) | SQ Innovation, Inc. | 2026-02-09 |
| Study of BMS-986453 in Newly Diagnosed Multiple Myeloma (NCT07333261) | Susan Bal | 2026-02-09 |
| RIG 101 Trial in Healthy Adults and Adults With Asthma (NCT07488897) | RIGImmune Inc. | 2026-02-09 |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (NCT07053917) | Johns Hopkins University | 2026-02-09 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (NCT07232602) | Merck Sharp & Dohme LLC | 2026-02-09 |
| A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood (NCT07308652) | Boehringer Ingelheim | 2026-02-09 |
| A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants. (NCT07358156) | Chong Kun Dang Pharmaceutical | 2026-02-09 |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (NCT07411560) | Novo Nordisk A/S | 2026-02-09 |
| GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia (NCT07372885) | University of Manchester | 2026-02-09 |
| Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer (NCT07236112) | C Ray Therapeutics | 2026-02-08 |
| A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) (NCT07349017) | Changchun BCHT Biotechnology Co. | 2026-02-07 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies (NCT07213830) | Ipsen | 2026-02-06 |
| A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (NCT07334860) | Merck Sharp & Dohme LLC | 2026-02-06 |
| A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body (NCT07368569) | Boehringer Ingelheim | 2026-02-06 |
| A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy (NCT07423117) | IntoCell, Inc | 2026-02-06 |
| Bioequivalence Study to Compare Imeglimin HCl 500 mg Film Coated Tablets Versus Twymeeg Tablets 500 mg (NCT07691177) | Humanis Saglık Anonim Sirketi | 2026-02-06 |
| Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum (NCT07401277) | West Virginia University | 2026-02-06 |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (NCT07280013) | C4 Therapeutics, Inc. | 2026-02-06 |
| A Study of PLB-002 in Advanced Solid Tumors (NCT07304128) | Primelink BioTherapeitics(ShenZhen) Limited | 2026-02-06 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants (NCT07262281) | Newsoara Biopharma Co., Ltd. | 2026-02-06 |
| Pharmacokinetic (PK) Evaluation of Nalmefene Formulations (NCT07543276) | Knoa Pharma LLC | 2026-02-06 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (NCT07314333) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-02-05 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (NCT07487363) | Hudson Biotech | 2026-02-05 |
| Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult Participants (NCT07409922) | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 2026-02-05 |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (NCT07250750) | ImmunAbs Inc. | 2026-02-05 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. (NCT07375758) | Beijing Mabworks Biotech Co., Ltd. | 2026-02-05 |
| An Antibody-armored Dendritic Cell in Patients With Solid Tumors (NCT07479667) | Shanghai Cell Therapy Group Co.,Ltd | 2026-02-05 |
| A Study of Elenestinib in Healthy Adult Female Participants (NCT07388511) | Blueprint Medicines Corporation | 2026-02-05 |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (NCT07287995) | Astellas Pharma Global Development, Inc. | 2026-02-05 |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (NCT07194044) | H. Lee Moffitt Cancer Center and Research Institute | 2026-02-05 |
| A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults (NCT07370584) | iVeena Delivery Systems, Inc. | 2026-02-04 |
| Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder (NCT07158853) | University of Minnesota | 2026-02-04 |
| A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity (NCT07400679) | Pfizer | 2026-02-04 |
| A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) (NCT07276958) | Eli Lilly and Company | 2026-02-04 |
| Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). (NCT07471789) | Gyala Therapeutics | 2026-02-04 |
| Methylene Blue in Total Knee Arthroplasty (TKA) (NCT07324954) | University of Miami | 2026-02-04 |
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (NCT07372625) | PMV Pharmaceuticals, Inc | 2026-02-04 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (NCT07480954) | Beijing Biotech | 2026-02-04 |
| A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. (NCT06797986) | Cellid Co., Ltd. | 2026-02-04 |
| FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (NCT07283094) | Montefiore Medical Center | 2026-02-03 |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer (NCT07325136) | Bristol-Myers Squibb | 2026-02-03 |
| Evaluate RLS-1496 Topical Cream for Actinic Keratosis (NCT07340697) | Rubedo Life Sciences, Inc. | 2026-02-03 |
| Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) (NCT07357519) | Lantheus Medical Imaging | 2026-02-03 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants (NCT07377539) | Jazz Pharmaceuticals | 2026-02-03 |
| A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (NCT07395024) | Astellas Pharma Global Development, Inc. | 2026-02-03 |
| Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (NCT07364214) | Arcus Biosciences, Inc. | 2026-02-03 |
| A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants (NCT07421778) | QurAlis Corporation | 2026-02-02 |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (NCT07480213) | Beijing Biotech | 2026-02-02 |
| Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer (NCT07589517) | Beijing Biotech | 2026-02-02 |
| Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (NCT07183709) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-02-02 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma (NCT07480941) | Beijing Biotech | 2026-02-02 |
| Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) (NCT07204977) | National Institute of Neurological Disorders and Stroke (NINDS) | 2026-02-02 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax (NCT07148180) | Jacqueline Garcia, MD | 2026-02-02 |
| Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor (NCT07331792) | Combined Military Hospital Abbottabad | 2026-02-02 |
| Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies (NCT07292818) | UNC Lineberger Comprehensive Cancer Center | 2026-02-02 |
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) (NCT07247266) | Akros Pharma Inc. | 2026-02-02 |
| Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma (NCT07551349) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC (NCT07467863) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC (NCT07510802) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (NCT07486089) | Beijing Biotech | 2026-02-02 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT06871410) | Roswell Park Cancer Institute | 2026-02-02 |
| Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation (NCT07130695) | Virginia Commonwealth University | 2026-02-02 |
| Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (NCT07480928) | Beijing Biotech | 2026-02-02 |
| A Study of GR1803 in Systemic Lupus Erythematosus (NCT07348055) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2026-02-02 |
| To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (NCT07374406) | JW Pharmaceutical | 2026-02-02 |
| Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (NCT06654193) | Hope Biosciences LLC | 2026-02-01 |
| Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients (NCT07370506) | Tanta University | 2026-02-01 |
| Dexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain (NCT07380139) | Ain Shams University | 2026-02-01 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (NCT07410676) | Essen Biotech | 2026-02-01 |
| Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy (NCT06222437) | Methodist Health System | 2026-02-01 |
| Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) (NCT06345027) | Baylor College of Medicine | 2026-02-01 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants (NCT07432698) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2026-02-01 |
| Kamuvudine-9 (K9) in Diabetic Macular Edema (NCT07458061) | Dr. Bryan Strelow | 2026-02-01 |
| Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis (NCT07203391) | St Vincent's Hospital, Sydney | 2026-02-01 |
| CAR-DC for End-Stage IPF (NCT07329959) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-02-01 |
| Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer (NCT07329894) | Beijing GoBroad Hospital | 2026-02-01 |
| Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. (NCT07421856) | Hebei Senlang Biotechnology Inc., Ltd. | 2026-02-01 |
| Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201 (NCT07333820) | Yonsei University | 2026-02-01 |
| Soy Tomato Juice to Improve Outcomes in Pancreatitis (NCT07447687) | Ohio State University | 2026-02-01 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease (NCT07404111) | Kriya Therapeutics, Inc. | 2026-02-01 |
| A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma (NCT07482059) | West China Hospital | 2026-02-01 |
| Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers (NCT07349589) | Daewon Pharmaceutical Co., Ltd. | 2026-02-01 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (NCT07410494) | Essen Biotech | 2026-02-01 |
| Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma (NCT07398963) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-02-01 |
| Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis (NCT06841068) | Wake Forest University Health Sciences | 2026-02-01 |
| A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (NCT07135466) | Sheba Medical Center | 2026-02-01 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy (NCT07341828) | Huashan Hospital | 2026-02-01 |
| Ripertamab for the Treatment of Myasthenia Gravis (NCT07372807) | Zhongming Qiu | 2026-02-01 |
| Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment (NCT06217094) | University of Florida | 2026-02-01 |